Overview

Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain

Status:
Completed

Trial end date:
2001-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this open-label, extension study is to characterize the safety, effectiveness, and impact on quality of life measures of long-term repeated dosing of OROS hydromorphone slow release (8, 16, 32 and 64 mg tablets) in patients with chronic low back pain.

Phase:

Phase 3

Details

Lead Sponsor:

Alza Corporation, DE, USA

Treatments:

Hydromorphone